Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Aclaris Therapeutics to announce earnings of ($0.16) per share and revenue of $1.3830 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. Aclaris Therapeutics had a negative return on equity of 55.89% and a negative net margin of 832.58%. On average, analysts expect Aclaris Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aclaris Therapeutics Price Performance

ACRS opened at $5.53 on Tuesday. The business has a 50 day simple moving average of $5.01 and a two-hundred day simple moving average of $4.24. The firm has a market capitalization of $772.32 million, a price-to-earnings ratio of -9.87 and a beta of 0.78. Aclaris Therapeutics has a one year low of $1.50 and a one year high of $5.88.

Wall Street Analyst Weigh In

ACRS has been the topic of several research analyst reports. Wedbush boosted their target price on Aclaris Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Wednesday, June 24th. UBS Group set a $10.00 price target on Aclaris Therapeutics in a research note on Thursday, April 16th. Piper Sandler lifted their price target on shares of Aclaris Therapeutics from $7.00 to $11.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, May 5th. They set a “buy” rating and a $12.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.50.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Invesco Ltd. grew its holdings in Aclaris Therapeutics by 409.0% in the first quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 45,864 shares during the period. Millennium Management LLC lifted its holdings in shares of Aclaris Therapeutics by 111.0% during the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after purchasing an additional 2,175,101 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Aclaris Therapeutics by 29.7% during the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock valued at $851,000 after purchasing an additional 127,366 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Aclaris Therapeutics by 108.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock worth $3,501,000 after purchasing an additional 1,282,042 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Aclaris Therapeutics by 25.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 623,792 shares of the biotechnology company’s stock worth $886,000 after purchasing an additional 125,071 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.